Loading
institutionsInstitution
LungenClinic Grosshansdorf
Specialist lung hospital near Hamburg whose thoracic oncology department, under Martin Reck, has led many of the pivotal immunotherapy trials in lung cancer, including KEYNOTE-024.
Also called: Lung Clinic GrosshansdorfAirway Research Center North (ARCN)
Overview
LungenClinic Grosshansdorf is a specialist hospital for lung disease outside Hamburg and a site of the German Center for Lung Research (Airway Research Center North). Its Department of Thoracic Oncology, headed by Martin Reck, was the lead centre for KEYNOTE-024, the 2016 trial that established first-line pembrolizumab for PD-L1-high non-small-cell lung cancer, and has contributed to most large lung cancer immunotherapy and small-cell lung cancer trials since.
Location
Großhansdorf, DE
Type
hospital
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#473 · 8 points (0 Newsweek + 0 NCI + 8 from 4 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to LungenClinic Grosshansdorf, including child institutions. 122 works · 3,018 citations · 66% open access · 30% clinical trials · 0% reviews.
Oncology works per year
132022
222023
252024
382025
242026
Most works
- Martin Reck44 works
- Martin Reck32 works
- Luis G Paz-Ares17 works
- Stephen V. Liu16 works
- Enriqueta Felip13 works
- Roy S. Herbst12 works
- Solange Peters11 works
- Minu K. Srivastava11 works
- Federico Cappuzzo10 works
- Melissa Lynne Johnson10 works
Most cited
- Thoracic oncology
- Lung cancer immunotherapy trials
- Small-cell lung cancer
Similar pages
- PersonMatthew D. Hellmann
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Lung cancer (all types), Non-small-cell lung cancer.
- TrialPEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- TrialZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- TrialA Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- TrialThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- TrialA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- PersonReinhard Büttner
Shares nationales Netzwerk Genomische Medizin Lungenkrebs, Non-small-cell lung cancer.